Clinical Trial Update: Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy [Phase 3]

View source ↗

Summary

Phase 3 study assessing linagliptin 5 mg once daily in type 2 diabetes patients with inadequate glycemic control on metformin; results were posted in 2013 after…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tradjenta (Linagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2013-06-03